Patent evergreening is a strategy employed by pharmaceutical companies to extend the life of a patent beyond its original expiration date. This involves making slight modifications to the original drug, such as changes in formulation, dosage, or delivery method, to obtain a new patent. While this practice is legal, it is often criticized for delaying the entry of generic competitors, thus keeping drug prices high for a longer period.
